The ground is shifting beneath the U.S. vaccine landscape. For decades, the CDC’s adoption of ACIP recommendations has provided a stable national baseline for coverage, requiring insurers to pay for a wide range of vaccines without cost-sharing. That framework is now in question. HHS Secretary Robert F. Kennedy Jr. has reshaped ACIP’s membership, dismissed CDC leadership, and cast doubt on the reliability of the federal immunization schedule. Most recently, President Trump used a White House autism event to question vaccine safety, suggesting altered vaccination schedules and linking vaccines to autism — claims swiftly rejected by medical experts. Together, these moves have left states, insurers, and employers to decide for themselves how far to go in sustaining vaccine access when federal guidance can no longer be relied upon.
How the ACA changed vaccine coverage
To see what the future might hold, it helps to remember what came before. Prior to enactment of the ACA in 2010, coverage of vaccines was fragmented and inconsistent:
- Children’s vaccines were often covered, but not always at no cost. Deductibles and copays could create financial barriers to access
- Adult vaccines were even more unevenly covered. Shingles was inconsistently covered and usually expensive for patients. Coverage for HPV vaccination beyond the adolescent window — so-called catch-up doses — was spotty and often came with significant out-of-pocket costs
- Medicare covered only a subset of vaccines under Part B, with others under Part D, typically with copays
- Medicaid coverage varied widely across states, with some covering a broad range of vaccines and others far more limited
The ACA standardized much of this by linking coverage to ACIP recommendations, creating a uniform national baseline: if ACIP said yes, coverage was guaranteed across Medicare, Medicaid-expansion states, and most private plans. At its September 2025 meeting, ACIP narrowed several recommendations: it rescinded the combined MMRV recommendation for children under age 4 (favoring separate MMR and varicella shots) and shifted COVID-19 vaccines from a universal recommendation for ages 6 months and up to shared clinical decision making for a more limited population. The agenda also flagged possible changes to the infant hepatitis B schedule and related Vaccines for Children determinations, with votes postponed to later sessions. Taken together, these moves signal a broader trajectory: ACIP is moving away from universal coverage mandates and toward narrower, more discretionary guidance — a shift that leaves payers and states to decide how much protection to sustain. Without ACIP’s endorsement, we risk sliding back toward the older patchwork.
The hostility exhibited by the administration toward vaccines is also evident by communications from HHS and the White House. This rhetoric adds to the climate of doubt surrounding federal vaccine policy and heightens pressure on states to step in.
Predictions by states
States will not respond uniformly if ACIP drops vaccine recommendations. Some will move quickly to preserve mandates, others will roll them back.
Blue-leaning states are likely to preserve or even expand mandates. California, Oregon, Washington, and Hawaii have already formed the West Coast Health Alliance to issue vaccine guidance explicitly based on science, distancing themselves from federal agencies they view as compromised. In the Northeast, New York, Pennsylvania, New Jersey, Massachusetts, Maine, Rhode Island, and Connecticut have launched the Northeast Public Health Collaborative to coordinate evidence-based vaccine guidance and public-health responses independent of shifting federal signals. Together, these regional coalitions reflect a clear determination among blue states to uphold consistent immunization standards, even as federal rules retreat.
Individual states are also taking their own steps. According to KFF, 26 states — 23 of them led by Democratic governors — have already announced or implemented vaccine policy changes in response to federal shifts, underscoring how blue states are moving quickly to fill the federal gap. Thirteen states have issued coverage requirements of COVID-19 vaccines, and four of these states — including California, Illinois, Maryland, and Massachusetts — have issued coverage requirements for other vaccines as well. In addition, 13 states have issued COVID-19 vaccine recommendations that differ from current ACIP/CDC recommendations, and another eight states plus the District of Columbia have issued their own recommendations covering the full set of vaccines, some of which diverge from ACIP/CDC guidance.
Most red-leaning states are either rolling back coverage requirements or failing to fill the void when federal rules weaken. Florida has gone furthest, planning to lift mandates on school vaccines for hepatis B, chickenpox, Hib influenza and pneumococcal diseases, such as meningitis. Unless vaccination requirements are updated through legislation, all other vaccinations required under Florida law to attend school, including vaccines for measles, polio, diphtheria, pertussis, mumps, and tetanus, will remain in place. KFF notes that three states — Nevada, Vermont, and Virginia — have authorized pharmacists to continue administering COVID-19 vaccines beyond current ACIP/CDC recommendations, ensuring access even after federal guidance narrowed. While KFF describes these three states as being Republican, Nevada is arguably a purple state, Vermont is blue at the federal level and split at the state level, and Virginia is arguably a blue-leaning purple state.
One important caveat: State mandates apply unevenly. Fully insured plans (about one third of the commercial market) sold by insurers must comply with state requirements. Self-insured employers, which cover most Americans with private insurance, are governed by federal ERISA law and not bound by state mandates. These employers can choose to follow state guidance, but they are not legally required to.
The result is a patchwork. Employees covered by an insurer in Oregon may see broad coverage, while workers at a self-insured manufacturing company in Texas may face far narrower access. And even within the same state, coverage can diverge sharply between people insured through state-regulated plans and those covered by self-insured employer exempt from state rules.
Predictions by insurers, Medicaid, and employers
Different types of plan sponsors will react differently if ACIP and the CDC step back from some of the vaccines currently on the federal immunization schedule. Some will follow mandates mechanically, others will make economic ROI judgments, and still others will respond to reputational or political pressures.
Multistate national insurers
Already used to juggling state-specific mandates (e.g., fertility coverage, autism services), these plan sponsors can be expected to comply where required, and drop or require cost sharing where not. It is unlikely that many will set a single national standard.
Regional or single-state insurers
Closer ties to local providers and regulators may lead to stronger alignment with state health departments. If local leaders prioritize coverage, these insurers are more likely to follow suit.
Medicaid agencies
Medicaid has two layers of funding at stake:
- Base federal match (FMAP): States can usually receive matching dollars for vaccines they decide to cover, even if ACIP no longer recommends them, as long as the service is part of the state plan
- Extra ACA incentive: Since 2010, states that cover all ACIP- and U.S. Preventive Services Task Force-recommended adult preventive services without cost sharing receive a one-percentage-point bump in their FMAP. If a vaccine loses ACIP recommendation, states can still cover it with the base match, but they would lose that extra bump for that service
In practice, states are most likely to keep covering vaccines that reduce short-term costs — for example, maternal Tdap or infant RSV protection that prevents expensive hospitalizations. By contrast, vaccines with benefits that show up decades later, like adult Hepatitis B or HPV catch-up, are more at risk of being dropped if budgets tighten.
Self-insured employers
Self-insured employers are likely to show the greatest internal variation. Large, brand-sensitive firms are far more likely to maintain vaccine coverage. These employers tend to be more sophisticated in benefit design and more attuned to reputational risks, making them reluctant to drop coverage even without a mandate. By contrast, employers with high workforce churn or a stronger focus on immediate cost savings may be quicker to scale back, though some high-exposure industries, like airlines or healthcare, may view continued vaccine coverage as essential to workforce protection and business continuity.
Predictions by vaccine type
Different vaccines will not all be treated the same. Some are almost certain to remain covered, others may be scaled back or face cost-sharing, and some are already excluded today.
Likely retained
- When it comes to respiratory vaccines (flu, pneumococcal, RSV, COVID-19 for high-risk groups), payers have strong incentives to maintain coverage. These vaccines prevent expensive, near-term hospitalizations, especially for vulnerable populations, making them the closest thing to “no-brainers” even without a mandate
- Core childhood vaccines (Tdap, MMR, varicella): Most are already embedded in state laws or public-health programs. Coverage will remain, though insurers may use stricter utilization management (e.g., proof of nonimmunity)
At risk of scaling back
- Shingles (Shingrix): Likely to remain covered, but may reappear with cost sharing for older adults. Dropping it outright would trigger member backlash
- HPV (adolescents vs. adults): Payers will likely maintain pediatric and adolescent coverage but may restrict adult “catch-up” vaccination for those not vaccinated earlier
- Hepatitis B: Payers will likely narrow coverage to high-risk groups. These vaccines are strongly supported by evidence, but without near-term cost offsets, they risk being sidelined
Already excluded / unlikely to change
- Travel vaccines: These are rarely covered today and are unlikely to be added in the future
When federal rules fall away
When federal rules fall away, vaccine coverage will fragment — a dynamic the country has seen before, most recently during COVID-19, when a patchwork of state policies complicated containment. Fully insured plans in mandate-heavy states will preserve access; self-insured employers will diverge based on budgets and values; Medicaid will cover strategically, especially where hospital costs loom large. The result will look less like today’s uniform baseline and more like the messy patchwork of pre-ACA days.
The decisions of states, insurers, and self-insured employers will not only reveal their true priorities; they will shape the future of preventive care in an era where federal guidance is no longer evidence-based. That prospect is deeply frustrating, given the proven value of many vaccines. Yet there is also reason for hope. If enough states, insurers, and employers sustain robust coverage, they can bridge the gap for many until the pendulum swings back at the federal level. The question is whether this moment becomes a temporary setback — or a lasting fracture in the nation’s preventive care system.
No Comments